Vimeo logo LinkedIn logo

Case Studies

npif stripes
Back to Case Studies
Liverpool ChiroChem scientists

Liverpool Chirochem II


Region:North West


Programme:Northern Powerhouse Investment Fund

Liverpool ChiroChem scientists

NPIF – Maven Equity Finance, part of the Northern Powerhouse Investment Fund and managed by Maven Capital Partners (“Maven”), has led a £2 million funding round for Liverpool Chirochem Limited (‘LCC), an international chemical technology business whose products form the building blocks to the research and development of new drugs. The NPIF – Maven Equity Fund invested £1 million, alongside the £1 million from the Government’s Future Fund.

NPIF – Maven Equity Finance originally invested £500,000 in 2018 to support the company through its ‘proof of concept’ phase and establish operations in the UK and China, as well as grow its initial team to 12 employees. Today’s transaction will help the business to rapidly scale up and expand its production capacity to service its growing customer base.

Since the company’s founding in 2014, LCC has produced products which provide pharmaceutical companies innovative processes for the research and development of new drugs. The company’s most notable product, 3D Chiral Scaffolds, are used by pharmaceutical companies all over the world.

LCC’s higher quality 3D compounds enable their customers to increase success probability, reduce trial costs and time and accelerate revenue generation.

Backed by a highly skilled, specialist management team, CEO Paul Colbon, a founding member of LCC, previously worked with Redx Pharma and AstraZeneca. Chairman and Director, Malcolm, has over 20 years industrial experience in speciality chemicals and advanced materials with ICI, Zeneca and Avecia and 15 years working at Board level with early-stage technology businesses servicing the Electronics and Life Science Sectors.

Paul Colbon, CEO and co-founder of LCC, said: “2020 was an outstanding year for LCC despite the challenges and continuing disruption of COVID. LCC’s stock of unique, diverse and high purity chemical compounds are expanding month on month. Securing these additional funds will enable the Team to accelerate investment in capital equipment, continuing the scale up of our production capability, enabling LCC to take advantage of the new and growing customer opportunities.”

Simon Robb, Portfolio Manager at Maven, said: “LCC is a global innovator creating specialist products that enable drug discovery and we’re delighted to continue to support such a pioneering company operating in a vital sector of the science technology space. Today’s transaction demonstrates our belief in how far the business has come and the future growth it can achieve. We look forward to working with Paul and the team as they drive the business forward.”

Asif Hamid MBE, Chair of the Liverpool City Region Local Enterprise Partnership (LEP), said: “Small businesses are the backbone of our economy and the Northern Powerhouse Investment Fund has provided valuable support to our business community since its launch in 2017. By helping innovative and ambitious companies such as ChiroChem grow and invest, NPIF has had a fantastic impact on unlocking business potential and creating jobs in the City Region.”

The Northern Powerhouse Investment Fund project is supported financially by the European Union using funding from the European Regional Development Fund (ERDF) as part of the European Structural and Investment Funds Growth Programme 2014-2020 and the European Investment Bank.

Maven Capital Partners UK LLP is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 495929

Editors Notes

Find Out More

If you would like to meet with one of NPIF's appointed Fund Managers to talk in more detail please go to Funds Available to find the Fund Managers operating in your area

Signpost microfinance icon


£25k – £100k

Microfinance page
Learn More
Debt finance icon of a road map

Debt Finance

£100k – £750k

Debt Finance page
Learn More
equity finance icon

Equity Finance

£50k – £2m

Equity Finance page
Learn More